Research & Development Activities and Commercialization of New Products to Propel Market Growth

For several decades, veterinary vaccines have played a key role in improving food security and as a result, human health. The medicine sphere wherein veterinary medicines constitute a significant share continues to evolve at a consistent pace. At present, innovations in the veterinary therapeutics market are largely made possible through advancements in technology and research & development activities.

Read Report Overview -

Over the past decade, a considerable amount of promising breakthroughs in the veterinary therapeutic field have paved the way for a host of specialty medicine. The significant rise in the number of pet animals worldwide, progress in surgical and medical capabilities pertaining to the treatment of animals, growing focus on improving the overall wellness of animals, significant progress in the development of new vaccines for an array of diseases, and discovery of new medication to curb the occurrence of new diseases are some of the key factors expected to influence the expansion of the veterinary therapeutics market during the forecast period.

Companies involved in the current veterinary therapeutics market landscape are actively engaged in research and development activities that have offered considerable promise. However, one of the glaring challenges that market participants are required to negotiate their way through is the evolving regulatory framework. Product development is likely to remain the cornerstone of the growth of the global veterinary therapeutics market, which is expected to reach US$ 58.5 Bn mark by the end of 2027.

Request Brochure of Report -

Breakthrough in Delivery of DNA Vaccines to Combat Avian Pathogens to Augment Market

Veterinary therapeutics have evolved at a considerable pace over the past decade, as drug developers continue to improve the overall efficacy of their products. Moreover, cost-efficiency, ease of administration, and suitability for mass vaccination are some of the other areas that have gained a great amount of consideration during the drug development phase.

In recent times, DNA vaccines have offered significant promise as an ideal solution for different poultry diseases, as they have exhibited no reversion to virulence and infection. At present, DNA vaccines have started to gain a great amount of traction, as they can be deployed against an array of pathogens and are comparatively easier to develop, manufacture, and store. However, despite offering these advantages, the adoption of DNA vaccines could slow down, owing to lack of capacity to induce high immunity and lack of availability for large-scale vaccination in the current scenario.

Request for Analysis of COVID-19 Impact on KSA Veterinary Therapeutics Market -

Vaccines and the development of new drugs will continue to progress at a consistent pace during the forecast period. Presently, in terms of product type, drugs are set to retain the majority of the share of the veterinary therapeutics market– a trend that is expected to continue during the forecast period. Although drugs will remain popular, the development of new vaccines will gain considerable momentum. DNA vaccines to address diseases in poultry are predominantly for combating bacterial, viral, and protozoan diseases.

Although DNA vaccines to tackle poultry diseases have gained momentum since 1993, FDA approval for these vaccines has gathered pace only in the past decade. Clinical trials and added research and development activities will continue to boost the adoption of vaccines within the global veterinary therapeutics market in the coming years.

Buy KSA Veterinary Therapeutics Market Report -

Companies to Rely on Inorganic Growth Strategies to Gain Ground

Companies operating in the current veterinary therapeutics market are expected to increase their market share by relying on inorganic growth strategies such as mergers & acquisitions. While expanding the product portfolio will continue to be an integral part of growth strategies for participants operating in the current market landscape, commercialization and development of new veterinary therapeutics are expected to gain momentum. For instance, in July 2019, Elanco Animal Health Incorporated announced that the company has completed the acquisition of Aratana Therapeutics.

With the acquisition, Elanco could expand its product portfolio and gain the exclusive rights to manufacture, develop, and commercialize the ‘cash cow’ Galliprant. While drug development will continue to revolve around companion animals as well as livestock animals, market participants are anticipated to continue to improve the efficacy of their veterinary therapeutics during the forecast period.

Browse More Trending Reports by Transparency Market Research:

Pediatric Implantable Port Market:

Pet Veterinary Drugs Market:

Organ-on-a-Chip Market:

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.


Mr. Rohit Bhisey

Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: [email protected]


Source link